Literature DB >> 16610929

Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice.

Bráulia C Caetano1, Oscar Bruña-Romero, Blima Fux, Erica A Mendes, Marcus L O Penido, Ricardo T Gazzinelli.   

Abstract

We have generated recombinant adenoviruses encoding three genetically modified surface antigens (SAGs) of the parasite Toxoplasma gondii, that is, AdSAG1, AdSAG2, and AdSAG3. Modifications included the removal of their glycosylphosphatidylinositol (GPI) anchoring motifs and, in some cases, the exchange of the native signal peptide for influenza virus hemagglutinin signal sequence. Adenovirus immunization of BALB/c mice elicited potent antibody responses against each protein, displaying a significant bias toward a helper T cell type 1 (Th1) profile in animals vaccinated with AdSAG1. Furthermore, the presence of parasite-specific IFN-gamma-producing T cells was analyzed by proliferation assays and enzyme-linked immunospot assays in the same animals. Splenocytes from immunized mice secreted IFN-gamma after in vitro stimulation with tachyzoite lysate antigen or with a fraction enriched for membrane-purified GPI-anchored proteins (F3) from the T. gondii tachyzoite surface. Epitopes recognized by CD8+ T cells were identified in SAG1 and SAG3, but not SAG2, sequences, although this protein also induced a specific response. We also tested the capacity of the immune responses detected to protect mice against a challenge with live T. gondii parasites. Although no protection was observed against tachyzoites of the highly virulent RH strain, a significant reduction in cyst loads in the brain was observed in animals challenged with the P-Br strain. Thus, up to 80% of the cysts were eliminated from animals vaccinated with a mixture of the three recombinant viruses. Because adenoviruses seemed capable of inducing Th1-biased protective immune responses against T. gondii antigens, other parasite antigens should be tested alone or in combination with those described here to further develop a protective vaccine against toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610929     DOI: 10.1089/hum.2006.17.415

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

1.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

Review 2.  Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain.

Authors:  Yasuhiro Suzuki; Qila Sa; Marie Gehman; Eri Ochiai
Journal:  Expert Rev Mol Med       Date:  2011-10-04       Impact factor: 5.600

3.  Determination of a Key Antigen for Immunological Intervention To Target the Latent Stage of Toxoplasma gondii.

Authors:  Qila Sa; Eri Ochiai; Ashish Tiwari; Jeremi Mullins; Nilabh Shastri; Corinne Mercier; Marie-France Cesbron-Delauw; Yasuhiro Suzuki
Journal:  J Immunol       Date:  2017-04-26       Impact factor: 5.422

4.  Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Authors:  Leoneide Érica Maduro Bouillet; Mariana Oliveira Dias; Natália Alves Dorigo; Andrew Douglas Moura; Bruce Russell; Francois Nosten; Laurent Renia; Erika Martins Braga; Ricardo Tostes Gazzinelli; Maurício M Rodrigues; Irene S Soares; Oscar Bruna-Romero
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

Review 5.  Production of recombinant proteins from protozoan parasites.

Authors:  José A Fernández-Robledo; Gerardo R Vasta
Journal:  Trends Parasitol       Date:  2010-02-26

6.  MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.

Authors:  Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

7.  Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice.

Authors:  Melina Laguía-Becher; Valentina Martín; Mauricio Kraemer; Mariana Corigliano; María L Yacono; Alejandra Goldman; Marina Clemente
Journal:  BMC Biotechnol       Date:  2010-07-15       Impact factor: 2.563

8.  Association of a NOD2 gene polymorphism and T-helper 17 cells with presumed ocular toxoplasmosis.

Authors:  Míriam S Dutra; Samantha R Béla; Alba L Peixoto-Rangel; Michaela Fakiola; Ariane G Cruz; Andrea Gazzinelli; Humberto F Quites; Lilian M G Bahia-Oliveira; Ricardo G Peixe; Wesley R Campos; Anna C Higino-Rocha; Nancy E Miller; Jenefer M Blackwell; Lis R Antonelli; Ricardo T Gazzinelli
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

9.  Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes.

Authors:  Eva-Maria Frickel; Nivedita Sahoo; Johnathan Hopp; Marc-Jan Gubbels; Mary Patricia J Craver; Laura J Knoll; Hidde L Ploegh; Gijsbert M Grotenbreg
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

10.  Vaccination against murine toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A.

Authors:  Young-Ha Lee; Dae-Whan Shin; Jae-Ho Lee; Ho-Woo Nam; Myoung-Hee Ahn
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.